Research Alert: Q1 Results Beat Estimates, Full-year 2025 Guidance Raised
BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $475
Bank of America Securities Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)
Morgan Stanley Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $548
Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $548 From $559, Keeps Overweight Rating
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $420
IDEXX Labs Price Target Cut to $420.00/Share From $450.00 by Stifel
IDEXX Laboratories Analyst Ratings
Piper Sandler Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $510
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $450
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $450
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $450
IDEXX Laboratories Analyst Ratings
Piper Sandler Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $510
Leerink Partners Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $525
Barclays Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $520
A Quick Look at Today's Ratings for IDEXX Laboratories Inc(IDXX.US), With a Forecast Between $460 to $550
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $559 From $550, Maintains Overweight Rating
IDEXX Labs Is Maintained at Neutral by B of A Securities
IDEXX Laboratories Analyst Ratings